Table 1.
Mild PD group.
| Subject | Sex | Age | Stage1 | UPDRS2 | Symptoms (years)3 | Medicines |
|---|---|---|---|---|---|---|
| 1 | M | 73 | 2.0 | 24.7 | 25 | L,Per, Tri |
| 2 | M | 75 | 2.5 | a | 16 | E, LS, Pro |
| 3 | M | 74 | 2.5 | 47.8 | 10 | Be, L, S |
| 4 | F | 79 | 3.0 | 15.8 | 4 | A, L, Pra, S |
| 5 | M | 75 | 2.5 | 27.0 | 8 | Bu, C, Lu, S |
| 6 | M | 77 | 3 | 28.5 | 9 | none |
| 7 | M | 58 | 2.0 | 21.5 | 8 | L, LS, To, Pe |
| 8 | M | 72 | 3 | 43.5 | 5 | Pe, S |
| 9 | M | 58 | 2.5 | 30.1 | 4 | L, S |
| Summary | 1F/8M | 71.2 ± 7.8 | 2.5 ± 0.4 | 29.8 ± 10.7 | 9.8 ± 6.7 | |
Demographic and clinical features of nine PD patients tested in the “off” state (UPDRS unified PD rating scale; motor subscale. In some cases patients were studied on more than one day. UPDRS scores were then averaged. In some cases, the UPDRS examination was not done for all items. In this case, the score was normalized to a total possible score of 108. Anti-parkinsonian and related medications: A, amantidine; Be, benztropine; Bu, buspar; C, clonazepam; E, vitamine E; L, levodopa preparation regular release; LS, levodopa preparation, sustained release; Lu, ludiomil; No, notriptyline; Pe, pergolide; Pra, pramipexole; Pro, propanolol; S, selegiline; Sy, synthroid; T, trihexyphenidyl; To, tolcapone; aUPDRS scores unavailable for this patient.
1Hoehn and Yahr stage.
2Maximum score 108.
3Refers to number of years since first remembered parkinsonian symptoms.